Newsfeeds Archive - Page 6 of 194

1 minute read

January 7, 7:44 PM

Shanghai Argo Biopharmaceutical Co., Ltd. ("Argo"), a biotechnology company focused on the discovery and development of next-generation RNAi therapeutics, today announced that it has entered into two exclusive

NVS

1 minute read

News

NanoString’s CosMx SMI Achieved Whole Transcriptome Imaging At Single-Cell Resolution

By Charles Gross

January 7, 4:10 PM

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the release of the first public dataset of the whole transcriptome obtained

NSTG

1 minute read

News

Vincerx Pharma Announced Clinical Efficacy Of Enitociclib In Combination With Venetoclax And Prednisone In Lymphoma; Investigators From The NIH Report 2 Partial Responses In 3 Peripheral T-cell Lymphoma Patients And 1 PR In 2 Double-hit Diffuse Large…

By Charles Gross

January 7, 4:04 PM

Vincerx Pharma, Inc. (NASDAQ:VINC) (“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced

VINC

1 minute read

QIAGEN To Return ~$300M To Shareholders Through A Synthetic Share Repurchase

By Charles Gross

January 7, 3:36 PM

QIAGEN N.V. announces a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock

QGEN

1 minute read

Caribou Biosciences Named Tim Kelly as Chief Technology Officer

By Charles Gross

January 7, 12:13 PM

Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tim Kelly to the newly created position of chief technology officer.

CRBU

1 minute read

News

Akoya Biosciences And Thermo Fisher Scientific Announced Earlier Sunday, A License And Distribution Agreement To Deliver Spatial Multiomics Workflow

By Charles Gross

January 7, 12:05 PM

Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced that it has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. The agreement enables Akoya to

AKYA

2 minute read

Senti Biosciences Said Reducing Its Workforce By ~37% As Part Of Prioritizing Its Investment In Lead Clinical Program

By Charles Gross

January 5, 5:07 PM

Senti Biosciences, Inc. (NASDAQ:SNTI) (“Senti Bio” or the “Company”), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit

SNTI

2 minute read

M&A
News

Ngm Biopharmaceuticals Confirmed It Received A Non-Binding Expression Of Interest From The Column Group Regarding Potential Acquisition Of All Outstanding Shares Of Common Stock Of The Company Not Already Owned By TCQ In A Going-Private Transaction

By Charles Gross

January 2, 8:36 AM

NGM Biopharmaceuticals, Inc. ("NGM Bio" or the "Company") today confirmed that it has received a non-bindingexpression of interest dated December 28, 2023 (the "EOI") from The Column Group,

NGM

1 minute read

Events
News

Longboard Pharmaceuticals Announced Monday It Would Host Call To Discuss Topline Data From PACIFIC Study, a Phase 1b/2a Clinical Trial For Bexicaserin In Participants With Developmental And Epileptic Encephalopathies Tuesday At 8:30 AM ET

By Charles Gross

January 2, 6:59 AM

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference

LBPH

1 minute read

JOYY Earlier Monday Announced It Received Written Notice From Affiliate Of Baidu Purporting To Terminate Share Purchase Agreement, Dated November 16, 2020

By Charles Gross

January 1, 12:55 PM

JOYY Inc. (NASDAQ:YY) ("JOYY" or the "Company," formerly known as YY Inc.), a global technology company, announced that the Company received a written notice (the "Notice") from an affiliate

BIDU